Sabbath Guitarist Iommi Updates Fans on Progress Against Lymphoma

Black Sabbath guitarist Tony Iommi announced at the beginning of 2012 that he had been diagnosed with follicular non-Hodgkins lymphoma.

Now, Iommi has updated fans via Sabbath's website following the conclusion of their North American tour. He explained:

Well we've finished the U.S. leg of our world tour. It was a bit longer than I would have liked as I've already been in hospital having another infusion. The tour was amazing though, you always hope it's going to go well but you never know, it's great to look out and see so many people of all ages. The new songs have been going down well, we've played them enough now so we're comfortable and that helps the performance. Many thanks to everyone who came to see us, South America next, and just like Australia this is a first time for Ozzy, Geezer and me together. All the best!

When Iommi talks of infusions, he's referring to infusions of a drug called rituximab, which is a monoclonal antibody that selectively kills specific cells in the body, namely cells that express a certain protein on their surfaces that is closely associated with his type of lymphoma.

Iommi continued:

The tour dates are arranged so that I can always get back for treatment. It's the only way I can manage my illness and keep on the road. I'd love to play more shows than we're doing but my health has to be sorted out first ... After each session I feel sick and tired, and that lasts for a week or so. I'm finding that it takes around 10 days to fully recover from each round of treatment, but if that's what it takes, I have to accept it.

From his explanation, it seems clear that Iommi is following a maintenance regimen that can run as long as two years. It is intended to keep his cancer at bay for as long as possible before he may or may not require additional and more aggressive treatment.

Source: antimusic

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap